Table 1.
Summary of published iPS papers
| Paper (Group) | Takahashi and Yamanaka (2006) (Yamanaka) | Okita et al. (2007) (Yamanaka) | Wernig et al. (2007) (Jaenisch) | Maherali et al. (2007) (Hochedlinger) |
|---|---|---|---|---|
| Selection | Fbx15 | Nanog | Oct3/4, Nanog | Oct3/4, Nanog |
| Cell type(s) | MEF, TTF | MEF | MEF, TTF | MEF, TTF |
| Frequency (iPS/fibroblasts) | 0.01%–0.5% | 0.001%–0.03% | Oct3/4: 0.08% Nanog: 0.005% | ND |
| Reprograming assays | ||||
| Functional | ||||
| Chimera contribution | +/−1 | + | + | + |
| Teratoma formation | + | + | + | + |
| Germline contribution | From MEF | From MEF | From TTF | |
| Cell fusion | + | |||
| Genetic/epigenetic | ||||
| Gene expression analysis | + | + | + | + |
| Gene-specific DNA methylation | + | + | + | + |
| Genome-wide DNA methylation | + | + | ||
| Imprinting | + | + | + | |
| Xi reactivation | + | |||
Experimental details of the four iPS papers are shown, in addition to the functional and other assays used to illustrate nuclear reprogramming.
1
Chimeric contribution limited to midgestation embryos in this study.
MEF, murine embryonic fibroblasts; TTF, tail-tip fibroblasts; ND, not disclosed; iPS, induced pluripotent stem cell.